"目录号: HY-13676
OthersAutophagy-
Megestrol醋酸盐能抑制HegG2，IC50为260 μM。
Progesterone ReceptorAutophagy
相关产品
Cycloheximide-TAK-242-LY294002-3-Methyladenine-(+)-JQ-1-SB 203580-SP600125-U0126-Enzalutamide-Actinomycin D-Olaparib-Doxorubicin hydrochloride-Dorsomorphin dihydrochloride-Mitomycin C-Bortezomib-
生物活性
Description
Megestrol Acetate is a synthetic progesteronal agent with an IC50 of 260 μM for the inhibition of HegG2.Target: Progesterone ReceptorMegestrol acetate, also known as 17α-acetoxy-6-dehydro-6-methylprogesterone, and sometimes abbreviated as MGA or MA, is a steroidal progestin and progesterone derivative (specifically, a 17-hydroxylated progesterone) with predominantly progestational and antigonadotropic effects. Megestrol acetate is a good candidate for muscle wasting treatment and future studies addressed at the interaction between the drug and protein turnover in human skeletal muscle should be performed.
Clinical Trial
NCT01968317
Xiaojun Chen-Fudan University-Shanghai 6th People's Hospital-Zhejiang Cancer Hospital-Shanghai Changning Maternity & Infant Health Hospital
Endometrial Atypical Hyperplasia-Endometrial Adenocarcinoma
October 2013
Phase 2
NCT00637572
Endo Pharmaceuticals-Quintiles, Inc.
HIV Infections-Cachexia-Anorexia-AIDS Wasting Syndrome-HIV Wasting Syndrome
December 2004
Phase 2
NCT00005975
Southwest Oncology Group-National Cancer Institute (NCI)
Breast Cancer-Hot Flashes
April 1998
Phase 3
NCT02644408
The First Affiliated Hospital of Henan University of Science and Technology
Stage III Esophageal Squamous Cell Carcinoma-Stage II Esophageal Squamous Cell Carcinoma
October 2014
Phase 3
NCT00483327
New York University School of Medicine
Atypical Endometrial Hyperplasia-Endometrial Carcinoma
June 2007
Phase 2
NCT00638079
Endo Pharmaceuticals-SFBC Anapharm
Pharmacokinetics-Bioavailability-Absorption
June 2006
Phase 1
NCT00066248
University of South Florida-National Cancer Institute (NCI)
Brain Tumor-Central Nervous System Tumors-Cachexia-Leukemia-Lymphoma-Myelodysplastic Syndromes-Myelodysplastic/Myeloproliferative Diseases-Unspecified Childhood Solid Tumor, Protocol Specific
June 2003
Phase 2
NCT00637806
Par Pharmaceutical, Inc.-PRA Health Sciences
Anorexia-Cachexia-Weight Loss
June 2006
Phase 3
NCT00637728
Par Pharmaceutical, Inc.-PRA Health Sciences
Anorexia-Cachexia-Weight Loss
June 2006
Phase 3
NCT00503516
Rottapharm Spain
Dementia
June 2007
Phase 2-Phase 3
NCT01501396
Washington University School of Medicine
Anorexia
September 2013
Phase 2
NCT00507949
Rottapharm Spain
Chronic Obstructive Pulmonary Disease
October 2006
Phase 2
NCT02595723
University of Texas Southwestern Medical Center-The Rogosin Institute
Cognitive Impairment
July 2015
Early Phase 1
NCT01237327
Pfizer
Metastatic Breast Cancer
November 2001
Phase 3
NCT00070148
Wake Forest University Health Sciences-National Cancer Institute (NCI)
Unspecified Adult Solid Tumor, Protocol Specific-Weight Changes
March 2004
Phase 3
NCT00575029
University of Arkansas
Adrenal Insufficiency
April 2004
NCT02980653
TTY Biopharm-Chang Gung Memorial Hospital
Head and Neck Cancer
May 2015
Phase 2
NCT00002182
Gamma Project - ACTU-NIH AIDS Clinical Trials Information Service
HIV Infections
NCT01200602
Mayo Clinic-National Cancer Institute (NCI)
Anorexia-Weight Changes
March 2011
Phase 2
NCT01943058
University of Southern California-National Cancer Institute (NCI)
Atypical Endometrial Hyperplasia-Endometrial Adenocarcinoma-Recurrent Endometrial Carcinoma-Stage IA Endometrial Carcinoma-Stage IB Endometrial Carcinoma-Stage II Endometrial Carcinoma-Stage IIIA Endometrial Carcinoma-Stage IIIB Endometrial Carcinoma-Stage IIIC Endometrial Carcinoma-Stage IVA Endometrial Carcinoma-Stage IVB Endometrial Carcinoma
March 2014
Phase 2
NCT00002067
Bristol-Myers Squibb
Anorexia-Cachexia-HIV Infections
Phase 3
NCT00002300
Bristol-Myers Squibb
Anorexia-Cachexia-HIV Infections
Phase 2
NCT00031707
Alliance for Clinical Trials in Oncology-National Cancer Institute (NCI)-NCIC Clinical Trials Group
Anorexia-Cachexia
March 2000
Phase 3
NCT00041275
National Medical Research Council (NMRC), Singapore-National Cancer Institute (NCI)
Liver Cancer
May 2002
Phase 3
NCT00637403
Par Pharmaceutical, Inc.-Covance-SFBC Anapharm
Healthy
May 2006
Phase 1
NCT00002465
St. Vincent Medical Center - Los Angeles-National Cancer Institute (NCI)
Breast Cancer-Endometrial Cancer-Malignant Mesothelioma
December 1987
Phase 1-Phase 2
NCT00004912
Northwestern University-National Cancer Institute (NCI)
Cachexia-Fatigue-Unspecified Adult Solid Tumor, Protocol Specific
January 2000
Phase 2
NCT00031785
Wake Forest University Health Sciences-National Cancer Institute (NCI)
Anorexia-Cachexia-Lung Cancer
September 2000
Phase 3
NCT00006799
Wake Forest University Health Sciences-National Cancer Institute (NCI)
Anorexia-Cachexia-Head and Neck Cancer-Quality of Life
October 2000
Phase 3
NCT00000737
National Institute of Allergy and Infectious Diseases (NIAID)-Roxane Laboratories-Bristol-Myers Squibb
Cachexia-HIV Infections-HIV Wasting Syndrome
Phase 1
NCT03024580
Instituto Nacional de Cancer, Brazil-Cancer Research UK Cambridge Institute
Breast Neoplasm
March 2017
Phase 2
NCT00002345
Bristol-Myers Squibb
Anorexia-Cachexia-HIV Infections
Phase 4
NCT00910091
Ipsen
Endometrial Cancer
August 2009
Phase 2
NCT00001079
National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections-HIV Wasting Syndrome
Phase 2
NCT00420563
Centre Oscar Lambret
Cancer
September 2006
Phase 2
NCT00503581
Gynecologic Oncology Group-National Cancer Institute (NCI)
High Grade Squamous Intraepithelial Neoplasia-Stage 0 Uterine Corpus Cancer
July 2007
Phase 2
NCT00729586
National Cancer Institute (NCI)
Endometrial Carcinoma-Recurrent Uterine Corpus Carcinoma-Stage IIIA Uterine Corpus Cancer-Stage IIIB Uterine Corpus Cancer-Stage IIIC1 Uterine Corpus Cancer-Stage IIIC2 Uterine Corpus Cancer-Stage IVA Uterine Corpus Cancer-Stage IVB Uterine Corpus Cancer
September 2008
Phase 2
NCT00004664
National Center for Research Resources (NCRR)-Northwestern University-Office of Rare Diseases (ORD)
Acquired Immunodeficiency Syndrome-HIV Wasting Syndrome-HIV Infections
June 1995
NCT01206478
Ann Davis, PhD, MPH, ABPP-Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)-University of Kansas Medical Center
Chronic Oral Food Refusal
August 2010
Phase 2
NCT02619266
Xinqiao Hospital of Chongqing-Chengdu University of Traditional Chinese Medicine
Anorexia-Cancer Cachexia
December 2015
Phase 2-Phase 3
NCT00016341
Gynecologic Oncology Group-National Cancer Institute (NCI)
Endometrial Cancer
May 2001
Phase 3
NCT00739830
Merck Sharp & Dohme Corp.
Endometrial Cancer
August 2008
Phase 2
NCT02269670
Emory University-Novartis
Estrogen Receptor-positive Breast Cancer-HER2-negative Breast Cancer-Progesterone Receptor-positive Breast Cancer-Recurrent Breast Cancer-Stage IIIA Breast Cancer-Stage IIIB Breast Cancer-Stage IIIC Breast Cancer-Stage IV Breast Cancer
November 2014
Phase 2
NCT00002680
Yale University
Breast Cancer
February 1994
Phase 2
NCT01670656
Merck Sharp & Dohme Corp.
Dysmenorrhea
January 2013
Phase 2
NCT00711607
Merck Sharp & Dohme Corp.-CRS Mannheim GmbH
Healthy
May 2007
Phase 1
NCT01723579
Merck Sharp